143 related articles for article (PubMed ID: 1246336)
41. Hemolytic uremic syndrome with hypocomplementemia, serum C3NeF, and glomerular deposits of C3.
Barré P; Kaplan BS; de Chadarévian JP; Drummond KN
Arch Pathol Lab Med; 1977 Jul; 101(7):357-61. PubMed ID: 577389
[TBL] [Abstract][Full Text] [Related]
42. [Early components of complement in glomerular depositions].
Berger J
Pathol Biol (Paris); 1975 Jun; 23(6):484. PubMed ID: 1105351
[No Abstract] [Full Text] [Related]
43. Redefining C3 glomerulopathy: 'C3 only' is a bridge too far.
Larsen CP; Walker PD
Kidney Int; 2013 Feb; 83(2):331-2. PubMed ID: 23364589
[No Abstract] [Full Text] [Related]
44. Nephritic factor, C3 splitting activity, C3 and factor B breakdown products in glomerular diseases.
De Vecchi A; Montagnino G; Scalia P; Tarantino A
Ric Clin Lab; 1980; 10(1):93-7. PubMed ID: 6781054
[No Abstract] [Full Text] [Related]
45. Disorders of the complement system in lipodystrophy.
Ipp MM; Minta JO; Gelfand EW
Clin Immunol Immunopathol; 1977 Mar; 7(2):281-7. PubMed ID: 862255
[No Abstract] [Full Text] [Related]
46. C3 and C5-cleaving properdin enzymes formed on zymosan incubated with human serum: the decay and the regeneration of the enzymes.
Fujita T; Takiuchi M; Matsumoto M; Nagaki K; Inai S
Int Arch Allergy Appl Immunol; 1977; 53(4):303-9. PubMed ID: 67089
[TBL] [Abstract][Full Text] [Related]
47. C3 glomerulopathy: what's in a name?
D'Agati VD; Bomback AS
Kidney Int; 2012 Aug; 82(4):379-81. PubMed ID: 22846813
[TBL] [Abstract][Full Text] [Related]
48. [Immunohistological studies in IgA nephropathy (author's transl)].
Tomino Y
Hokkaido Igaku Zasshi; 1980 Mar; 55(2):123-30. PubMed ID: 6997157
[No Abstract] [Full Text] [Related]
49. Receptors for the third component of complement in the human glomerulus.
Alarcon-Segovia D
J Rheumatol; 1976 Dec; 3(4):327-8. PubMed ID: 139474
[No Abstract] [Full Text] [Related]
50. Modification of glomerular immune complex deposits.
McCluskey RT
Lab Invest; 1983 Mar; 48(3):241-4. PubMed ID: 6219247
[No Abstract] [Full Text] [Related]
51. Renal transplantation in mesangioproliferative glomerulonephritis (MPGN): relationship between the high frquency of recurrent glomerulonephritis and hypocomplementemia.
Berthoux FC; Ducret F; Colon S; Blanc-Brunat N; Zech PY; Traeger J
Kidney Int Suppl; 1975 Feb; (3):323-7. PubMed ID: 1099312
[No Abstract] [Full Text] [Related]
52. The properdin pathway: mechanisms of complement activation and analogies to the classical pathway.
Fearon DT; Austen KF; Ruddy S
Rheumatology; 1975; 6():2-16. PubMed ID: 1105744
[No Abstract] [Full Text] [Related]
53. C3 metabolism in acute glomerulonephritis: implications for sites of complement activation.
Endre ZH; Pussell BA; Charlesworth JA; Coovadia HM; Seedat YK
Kidney Int; 1984 Jun; 25(6):937-41. PubMed ID: 6236326
[TBL] [Abstract][Full Text] [Related]
54. Immunohistochemistry of glomerulonephritis.
Berger J; Yaneva H; Hinglais N
Adv Nephrol Necker Hosp; 1971; 1():11-30. PubMed ID: 5006252
[No Abstract] [Full Text] [Related]
55. Complement deposition in the kidney.
Berger J
Adv Nephrol Necker Hosp; 1974; 4():37-48. PubMed ID: 4219998
[No Abstract] [Full Text] [Related]
56. Immunofluorescence patterns in chronic membranoproliferative glomerulonephritis (MPGN).
Belgiojoso GB; Tarantino A; Bazzi C; Colasanti G; Guerra L; Durante A
Clin Nephrol; 1976 Jul; 6(1):303-10. PubMed ID: 782750
[TBL] [Abstract][Full Text] [Related]
57. Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis.
Hiramatsu M; Balow JE; Tsokos GC
J Immunol; 1986 Jun; 136(12):4451-5. PubMed ID: 3011894
[TBL] [Abstract][Full Text] [Related]
58. C3 concentrations can be normal in patients with C3 glomerulopathy secondary to C3 nephritic factor.
Anderson H; Van Voorthuizen M; O'Donnell J; Beck S
J Clin Pathol; 2024 Jun; 77(7):503-506. PubMed ID: 38538072
[TBL] [Abstract][Full Text] [Related]
59. The incorporation of C3 nephritic factor (C3NeF) into a stabilized C3 convertase, C3bBb(C3NeF), and its release after decay of convertase function.
Daha MR; Austen KF; Fearon DT
J Immunol; 1977 Sep; 119(3):812-7. PubMed ID: 894027
[No Abstract] [Full Text] [Related]
60. [Immunohistological studies of renal diseases. II. The clinical and histopathological significance of complement deposition in glomeruli (author's transl)].
Sato M
Nihon Jinzo Gakkai Shi; 1980 Oct; 22(10):1347-60. PubMed ID: 7017209
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
